IMMUNO-ONCOLOGY XCHANGE
2024
San Diego, February 27th

Welcome to hubXchange’s Immuno-Oncology Xchange San Diego 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing immuno-oncology therapies, through a series of roundtable discussions. 
Discussion topics will cover Immune Biomarkers, Translational Research, and Clinical Development.
Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Handlery Hotel San Diego, 950 Hotel Circle North, San Diego CA 92108

SNAPSHOTS OF DISCUSSION TOPICS

  • Predictive biomarkers for IO treatment used in clinical practice now and in the future
  • The rise of spatial omics technologies and their potential for new biomarker discovery
  • Translational strategies to develop clinically safe and effective immune cell engagers
  • How to select the right translational screening model to monitor IO agents
  • Early signals of efficacy, biomarkers and confidence in early clinical I/O trials
  • How to maximize clinical success: Patient selection strategies beyond target expression

Full Xchange Agenda

Click on each track for detailed agenda

Immune Biomarkers

Time
Titles and Bullets
Facilitator
8:00 – 8:30
Registration 
8:30 – 9:00

Opening Keynote Presentation

In Vitro Assays for Preclinical Drug Development: Realities and Limits

Increased understanding of the complex tumor microenvironment and its interactors has boosted therapeutic interest and highlighted the importance of the development of innovative in vitro bioassays to represent all the players of the cancer immune response and thereby potentially provide pivotal information on the functional dynamics of candidate therapeutics. Using high quality cells, these in vitro assays can accelerate the drug development process and support lead candidate selection.
 

Sofie Pattyn (CTO and founder, ImmunXperts, a Q2 Solutions Company) has over 25 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development with a focus on functional assays for immunogenicity, immune-oncology and Cell and Gene Therapy products. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.

Sofie Pattyn
9:05 – 10:05

Pharmacodynamic and predictive biomarkers: Choosing the right strategy from preclinical to clinical stages

  • What are some of the strategies to identify a ‘good’ PD biomarker in early stages (e.g., preclinical)? Is a PD response sufficient enough?
    What current technologies support best PD assessments?
  • What are the challenges in identifying a PD biomarker: Technological challenges vs biological challenges (e.g., tissue availability)
    Does a PD biomarker need to predict clinical response?
  • Is a predictive biomarker needed for successful IO therapies?
  • Can a PD biomarker evolve into a predictive Biomarker? Why or why not?
  • What correlations are needed to enable a PD biomarker becoming a predictive biomarker?
    What challenges need to be considered for the development of a predictive biomarker (e.g., disruptive vs widely accepted technologies)?

Scientific Leader in Immuno-Oncology and Cell & Gene Therapy Drug Development. Trained immunologist with expertise in translational research and preclinical and clinical biomarker development for CAR-T, Immuno-oncology and small molecule therapies for Phase I/II or III clinical trials. Advanced R&D goals through collaboration with KOLs leading to multiple peer reviewed manuscripts. Led the publication of cross-industry white paper in CAR-T immune monitoring. Mentored multiple associates in efficiently managing projects to achieve time- and business-critical goals. Evaluated and implemented new technologies for scientific advancements (e.g., HPFC) and laboratory automation solutions (Liquid handlers) as well as data analysis (AI based flow cytometry data analysis). Championed the development, validation and implementation (under GXP regulations) of multiple biomarker monitoring panels (>30) in AML/CLL/MM/AML and DLBCL etc., disease settings. Proficient at business development project proposals and portfolio prioritization. Experienced in regulatory document submissions including BAR/BDR and briefing books

Shyam Sarikonda
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:45 – 11:15
1-2-1 Meetings/Networking Break
11:15 – 11:25
Morning Refreshments
11:25 – 12:25

Developing autoantibody signatures to predict disease recurrence and immune-related adverse events in patients receiving adjuvant immunotherapy

  • Do autoantibody signatures / biomarkers offer advantages over DNA, RNA and protein biomarkers?
  • Can autoantibody profiles be used as a tool for treatment monitoring?
  • What are the best approaches for identifying autoantibody signatures?
  • What are the preferred platforms for discovering and validating autoantibody signatures?

Scott Paschke is focused on driving a business strategy that helps clients accelerate their research and discoveries using innovative tools and services offered by CDI Labs. Scott has over 20 years of experience in the biotechnology sector working with renowned R&D reagent companies. Prior to joining CDI Labs, Scott was Director of Business Development at Active Motif, and was President and Chief Technology Officer at Lake Placid Biologics. He also held leadership positions at Serologicals Corporation, Lake Placid Biologicals and Upstate Inc.  Scott received a BA in biology and a MA in biochemistry from State University College at Buffalo.

PIC-Paschke-HiRes
12:25 – 13:25
Networking Lunch
13:25 – 13:55

Spotlight Presentation

Advances in Split Pool Combinatorial Barcoding

The average number of cells profiled per single cell study is doubling every year. The utilization of single cell data has evolved over time and is becoming a more heavily relied upon resource to drive new hypotheses on disease and generate computational models across large research consortiums and clinical studies. As the needs for large amounts of high-quality single cell data evolve, it is the responsibility of single cell technology providers to accommodate these needs. It is our goal at Parse to provide a scalable and flexible solution such that single cell studies can be scoped and designed accordingly to what is needed to appropriately address the research question, rather than scoped and designed around the limitations of the single cell technology being used. Since split pool combinatorial barcoding’s introduction to the field seven years ago, Parse has made significant improvements in its single cell RNA-seq technology in addition to expanding into profiling different modalities within single cells. The latest advancements in Parse’s technology development pipeline in addition to demonstration of benchmarking comparisons to other technologies will be shared.

Julie Gerardi is Vice President of Business Development and Strategy at Parse Biosciences, where she oversees pharma relations and business to business strategy. Prior to joining Parse, Julie headed the Biological Modeling Division of Tempus Labs, where she managed pharma strategy involving organoid, single cell and spatial transcriptomic programs. Prior to that she was a member of the Tempus Alpha unit, where she managed their investment and business partnerships. She has held commercial positions in startup and fortune 500 companies. She enjoys finding ways for pharma and industry to work together to drive innovation.

Julie Gerardi
14:00 – 14:30

1-2-1 Meetings/Networking Break

14:35 – 15:05
1-2-1 Meetings/Networking Break
15:05 – 15:15

Afternoon Refreshments

15:15 – 15:45

Presentation

Rapid Generation of Antibodies for Blockade of TIGIT and PD1 Immune Checkpoint Inhibitors

Antibodies are powerful tools in target validation studies and translational research which also have the potential to go on and become therapeutic candidates
The ability to rapidly and cost-effectively generate large numbers of antibodies in a variety of different formats relevant to translational studies can be a very useful resource to gather data on biomarkers
Bio-Rad has combined SpyTag technology with antibody phage display to add speed and format versatility to our custom antibody service offering, including the ability to generate bispecific antibody combinations in around 90 minutes. In the presented case studies we provide a demonstration of how antibodies that are inhibitory to the TIGIT-CD155 and PD1 and PDL-1 interactions were generated in as little as 10 weeks. Selected candidates from the early studies were then further characterized whilst benchmarking against, and comparing to, antibody drugs in late phase clinical trials

Birthe is a technical sales specialist for Bio-Rad’s Custom Antibody Service and supports customers leveraging Bio-Rad’s innovative Pioneer Antibody Discovery Platform for their biotherapeutic discovery campaigns. Prior to joining Bio-Rad, she gained several years of experience in antibody discovery as an Associate Director at Alloy Therapeutics, where she led the In vivo Antibody Discovery team, and proceeding that as a Scientist in Antibody Discovery and Protein Engineering at Medimmune. She received her PhD from the University of Freiburg, Germany and completed her postdoctoral training at the University of California, San Francisco.

Birthe Jessen-Park
15:50 – 16:50

Overcoming limited tumor tissue availability: biomarker identification in blood for improved cancer diagnosis and monitoring

  • Advantages and limitations of each approach: What are the pros and cons of each approach?
  • Comprehensive blood-based assessment: Can blood measurements comprehensively address all biomarker and monitoring questions?
  • Validation of blood-based approaches: Is it necessary to evaluate both approaches for validation when considering a blood-based approach exclusively?
  • Mandatory tumor tissue biopsies in clinical trials: Can tumor tissue biopsies be a mandatory requirement in clinical trials for any indications?

Sonia Feau is Director of Biology at Onchilles Pharma and is responsible for managing activities related to the overall execution of R&D initiatives to move innovative therapeutic drug candidates into the clinic and advance Onchilles’ platform and future product portfolios. Sonia has 20 years of immuno-oncology experience. Prior to Onchilles Pharma, Sonia worked at Oncorus where she led the Immunology group responsible for designing, optimizing and evaluating new immune enhancer payloads to be expressed by oncolytic viruses, at Merck & Co. and Merrimack Pharmaceuticals, she proposed and evaluated several new immuno-oncology targets.
Sonia’s experience in Immunology spans both innate and adaptive immune responses. She received her post-doctoral training at the La Jolla Institute for Immunology in San Diego, where she studied CD8 memory T cells. Sonia received her Ph.D. in Immunology and Biotechnology from the University of Milano-Bicocca, Italy and University Toulouse III, France studying dendritic cells biology.

Sonia Feau
16:50 – 17:50
Drinks-Canape Reception

Partners

Immuno-Oncology Xchange | San Diego 2024
Register